HER2 PET/CT Imaging for Advanced Lung Cancer
Part of Cancer, Lungs & breathing clinical trials.
This study uses a special PET/CT scan to see how a radioactive tracer called Zr-trastuzumab collects in your lung cancer cells. The results will help doctors understand which patients with certain HER2 changes might benefit from HER2-targeted treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and willing to follow all study rules.
- Your lung cancer must have a specific HER2 change: either a high HER2 level (called overexpression) or an activating HER2 mutation found by a special gene test.
- Your cancer must have grown after at least one round of platinum-based chemotherapy, and you must be about to start a new treatment.
- You need to have at least two tumors on a scan that are at least 2 cm wide and can be measured.
- You must be able to have a PET/CT scan and provide a recent tumor sample.
- Your blood counts, liver, and kidney function must be adequate (routine blood tests will check this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special PET/CT scan to measure a protein called HER3 in your tumors. The scan uses a radioactive version of the drug patritumab deruxtecan (HER3-DXd). This test may help doctors understand how much HER3 is in your cancer and decide if HER3-targeted therapy could work for you.
This trial tests whether a new imaging agent called TGW211 can help doctors see HER2-positive cancers more clearly on scans. It may lead to better ways to track these cancers in the future.
This study tests whether using PET scans (a special imaging technique) to monitor how your HER2-positive breast cancer responds to treatment before surgery can help doctors choose the best treatment plan for you. The goal is to improve outcomes by personalizing therapy based on how your tumor responds.
This early-phase study uses a special PET scan with a drug tagged for imaging to predict how well HER2-targeted treatments will work. It may help doctors choose the most effective therapy for HER2-positive breast cancer.
This study uses a radioactive tracer to see how much HER2 protein is on your breast cancer cells. The scan may help doctors understand the type of HER2 you have and choose the best treatment.
This trial uses a special PET scan (HER2-PET) to see if a targeted drug (trastuzumab deruxtecan) works better for your type of metastatic breast cancer. The goal is to match the treatment to how much HER2 protein your tumors show.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.